Sufentanil sublingual tablet system: From rationale of use to clinical practice

Alessandro Vergari, A. Cortegiani, Marco Rispoli, Flaminia Coluzzi, F. Deni, Y. Leykin, F. Luca Lorini, P. P. Martorano, A. Paolicchi, E. Polati, M. Scardino, A. Corcione, A. Giarratano, Marco Rossi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

The control of post-operative pain in Italy and other western countries is still suboptimal. In recent years, the Sufentanil Sublingual Tablet System (SSTS; Zalviso; AcelRx Pharmaceuticals, Redwood City, CA, USA), which is designed for patient-controlled analgesia (PCA), has entered clinical practice. SSTS enables patients to manage moderate-to-severe acute pain during the first 72 postoperative hours directly in the hospital setting. However, the role of SSTS within the current framework of options for the management of post-operative pain needs to be better established. This paper presents the position on the use of SSTS of a multidisciplinary group of Italian Experts and provides protocols for the use of this device.
Lingua originaleEnglish
pagine (da-a)11891-11899
Numero di pagine9
RivistaEuropean Review for Medical and Pharmacological Sciences
Volume24
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • Clinical practice
  • Surgery
  • SSTS
  • Neuropathic pain

Fingerprint

Entra nei temi di ricerca di 'Sufentanil sublingual tablet system: From rationale of use to clinical practice'. Insieme formano una fingerprint unica.

Cita questo